Related Experiment Video

Updated: Dec 20, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.3K

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Justin T Ernst1, Peggy A Thompson2, Christian Nilewski3

  • 1Inception Therapeutics, 6175 Nancy Ridge Drive, San Diego, California 92121, United States.

Journal of Medicinal Chemistry
|May 30, 2020
PubMed

Insights

Researchers developed eFT226 (Zotatifin), a novel compound targeting cancer by inhibiting protein translation. This drug candidate shows significant antitumor activity and improved properties for clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Protein translation dysregulation drives cancer pathogenesis.
  • Eukaryotic initiation factor 4A (eIF4A) is crucial for cap-dependent protein synthesis and a target in cancer.
  • Flavagline natural products inhibit protein synthesis but have limitations for therapeutic use.

Purpose of the Study:

  • To design novel chemotypes with improved drug-like properties targeting eIF4A.
  • To elucidate the mechanism of action and mRNA selectivity of eIF4A inhibitors.
  • To identify compounds with significant antitumor activity for clinical development.

Main Methods:

  • Ligand-based drug design strategy.
  • Mechanistic studies on mRNA sequence selectivity and target gene regulation.
  • Preclinical evaluation of compound efficacy and physicochemical properties.

Main Results:

  • Identified eFT226 (Zotatifin) with optimized physicochemical properties.
  • Demonstrated significant antitumor activity of eFT226.
  • Elucidated the mechanism involving stabilization of translation-incompetent eIF4A-mRNA complexes.

Conclusions:

  • eFT226 (Zotatifin) is a promising therapeutic candidate for cancer treatment.
  • The compound exhibits potent antitumor effects supported by its mechanism of action.
  • Optimized drug-like properties and efficacy support eFT226's clinical development.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Rapid In Vivo Fixation and Isolation of Translational Complexes from Eukaryotic Cells14:29

Rapid In Vivo Fixation and Isolation of Translational Complexes from Eukaryotic Cells

Published on: December 25, 2021

4.6K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
38.0K
Transcription Elongation Factors02:35

Transcription Elongation Factors

Transcription elongation is a dynamic process that alters depending upon the sequence heterogeneity of the DNA being transcribed. Hence, it is not surprising that the elongation complex's composition also varies along the way while transcribing a gene.
The transcription elongation is regulated via pausing of RNA polymerase on several occasions during transcription. In bacteria, these halts are necessary because the transcription of DNA into mRNA is coupled to the translation of that mRNA...
12.9K
Transcription Initiation01:47

Transcription Initiation

Initiation is the first step of transcription in eukaryotes. Prokaryotic RNA Polymerase (RNAP) can bind to the template DNA and start transcribing. On the other hand, transcription in eukaryotes requires additional proteins, called transcription factors, to first bind to the promoter region in the DNA template. This binding helps recruit the specific RNAP that can assemble on the DNA and start transcription.
The promoters and enhancers and their accessory proteins allow tight regulation of...
19.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.1K
Eukaryotic RNA Polymerases00:58

Eukaryotic RNA Polymerases

RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
26.4K